Alzheon raises $100M; Regeneron ends mid-stage trial

Plus, news about Genmab, BioNTech, Bristol Myers Squibb, BridgeBio, Junshi, Tevogen, Actuate, GSK, Ochre Bio, Evotec and ProKidney:

Alzheon raises $100M Series E: The company’s lead program is currently in a Phase 3 study for early Alzheimer’s disease that’s expected to be completed this year. Alzheon said the funds will help support manufacturing and potential commercialization efforts for ALZ-801. — Max Gelman

Regeneron cuts mid-stage trial: The drugmaker terminated a mid-stage test of its antibody REGN4461 (also known as mibavademab) in adults with familial partial lipodystrophy, a rare genetic disorder. The decision does not impact another Phase 2 study in patients with generalized lipodystrophy, a company spokesperson told Endpoints News. Eli Lilly is also testing whether the antibody, when given in combination with its weight loss drug Zepbound, is better at reducing weight than Zepbound alone. That Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks